Johnson Johnson shares JNJ rose in premarket trading Tuesday after the consumer goods and pharmaceuticals company posted higher than expected third-quarter profits and raised its full-year guidance. - based company reported net income of $3.667 billion, or $1.37 a share, for the quarter, up from $3.554 billion, or $1.33 a share, in the year-earlier period The adjusted per share earnings came to $2.60, ahead of the $1.35 FactSet consensus. Sales rose to $23.338 billion from $21.082 billion, missing the $23.642 billion FactSet consensus. CEO Alex Gorsky said earnings were driven by strength in pharma, a continued recovery in medical devices and consumer health growth. Consumer sales rose 3.3% to $3.700 billion, medical sales rose 13.7% to $12.994 billion and pharmaceutical sales rose 8% to $6.644 billion. The company is now expecting full-year adjusted revenue of $9.77 to $9.82, a step up from the guidance offered in July of $9.60 to $9.70. It expects sales to range from $90.3 billion to $90.8 billion, up from past forecast of $90.0 billion to $90.8 billion. Including its COVID 19 vaccine, it expects sales to range from $92.8 billion to $93.3 billion. The FactSet consensus is for earnings of $9.71 and sales of $94.4 billion. Shares have gained 1.7% in the year to Monday, while the Dow Jones Industrial Average gained 15% and S&P 500 SPX gained 19.5%.